Tabulated adverse events from Phase 3 trials (4,263 participants who received APEXXNAR) and Prevenar 13 postmarketing experience1
*Events reported spontaneously in Prevenar 13 postmarketing experience; therefore, the frequencies could not be estimated from the available data and are considered as not known.
†Not reported in the adult Phase 3 trials of APEXXNAR; therefore, the frequency is not known.
§Event reported in clinical trials with Prevenar 13 with very common frequency (≥ 1/10).
20-valent pneumococcal conjugate vaccine for adults that helps protect against pneumococcal disease originating from vaccine-type serotypes1,2
Find out more about invasive and non-invasive pneumococcal infections, symptoms and statistics
Key information about dosing, administration and storage for APEXXNAR1
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021